Why Novartis Is Paying $2B for a Cancer Drug That Hits the Same Target as One of Its Own Products

Novartis already markets the PI3Kα inhibitor Piqray for breast cancer, but acquiring a Synnovation Therapeutics subsidiary brings an early clinical program that the pharma company claims could be best in the class of next-generation therapies for the target. Competitors include Eli Lilly, Relay Therapeutics, and OnKure Therapeutics. The post Why Novartis Is Paying $2B for…

Read More

Beyond Generative AI

By BENJAMIN EASTON Healthcare’s administrative burden is not a documentation problem. It is a workflow problem. Healthcare’s next leap depends on agentic systems that can actually do the work Over the past year, healthcare organizations have widely adopted generative AI for an array of documentation-related activities such as drafting appeal letters, producing patient-friendly summaries, and…

Read More

The Saga of Utah’s Rx Refill Bot: A Bold Bet on AI & Researchers Who Cried Foul

Utah is piloting an AI system developed by Doctronic to autonomously handle routine prescription refills, aiming to reduce delays and boost medication adherence. But a report from Mindgard AI claiming that there are vulnerabilities in the company’s chatbot underscores the broader challenge regulators and developers face in ensuring healthcare AI systems remain safe and reliable…

Read More